

Overview

- 3427 participants
- 11 sites
- 4 provinces
- 5 health networks
- 6 cancer types

Welcome MUHC to the Exactis Team!

Exactis welcomes the 11th site to the network. Under the leadership of Dr. Jonathan Spicer, the McGill University Health Center will be recruiting primarily lung as a first cohort. Congrats Emad Tawfik and Nick Bertos on recruiting your 61st patient since Jan 23rd!


Changes in Job Title

Following discussions with the PMT Agent Team, it was agreed that a change of job title to **PMT Coordinator** would better reflect their role. Feel free to update your resumé.

Upcoming PMT Agent Team Meeting

PMT Agents (Mark Gichuru, Renée Bernatchez, Stephanie Crapoulet) will meet in early March to discuss matters surrounding PMT. If you have any topics you'd like us to discuss please forward them to your respective PMT Site Manager.

PMT Portal Statistics




Investigator Initiated Trial Competition

This is a friendly reminder of the Exactis Investigator Initiated Clinical Trial competition that will award \$1M to help fund an interventional precision oncology study in the Exactis Network. Interested PIs at Network sites are strongly encouraged to submit Letters of Intent by the **February 28, 2019 deadline**. Please direct any questions regarding the competition to Andrew Slack; aslack@exactis.ca, or 514-282-4523 # 220

Cohorts to profile

Preparations for molecular profiling are underway. After strategic discussions with key opinion leaders (KOLs) and the PI Coordinating committee (PICC), we have prioritized several cancer cohorts. The discussions with the KOLs and PICC were wide ranging and took into account factors including unmet need, disease relevance, availability of tissue, rates of progression, disease prevalence and others. Additional cohorts will be announced as we progress throughout the year. The Exactis team will provide the lists of retrospective patients to the PMT Coordinator. We ask that PMT Coordinators focus their recruitment efforts on these cohorts. Instructions will be provided in the coming weeks.

| Cancer | Cancer subtype | Timing |
|------------|---|------------|
| Breast | Early stage (Stage I and II) breast cancer with residual disease post-neoadjuvant therapy | Early 2019 |
| Colorectal | Stage IV with resected mets within last 12 months | Early 2019 |
| Colorectal | Stage IV diagnosed within the last 6 months | Early 2019 |



Fabrice Yoboua
fyoboua@exactis.ca

Innovation Exactis
5450 Ch. Côte-des-Neiges #522
Montréal, QC H3T 1Y6



Garyfallia (Rosa) Christodouloupoulos
gchristod@exactis.ca



Expanding leadership to PMT

2019 is an important year for PMT. Many important goals are to be reached which include reaching 2500 patients/year enrolment rate, molecular profiling of PMT patients and the IIT competition. In order to achieve these goals, we expanded the leadership team in the PMT project; Suzan McNamara and Mathilde Couetoux du Tertre who presently oversee study management of clinical trials will also oversee PMT patient enrolment, site management, and patient matching to clinical trials.



Suzan McNamara, Vice President Clinical Operations

As the former Director of Clinical and Translational research at Q-CROC, Suzan brings her experience in the development and management of oncology clinical trials and translational biomarker biopsy-driven studies.

Suzan obtained her PhD in Experimental Medicine from McGill University where her studies focused on mechanisms of cancer resistance. Following her doctorate, she worked as a Clinical Trial Coordinator at the Jewish General Hospital and at Health Canada as an Assessment Officer where she was responsible for the evaluation, regulation and licensing of health products.



Mathilde Couetoux du Tertre, Director of Clinical Operations

Mathilde has over 9 years' experience managing oncology clinical trials as a Project Manager and a Clinical Research Associate. As a former Project Manager at Q-

CROC, Mathilde brings her scientific and clinical expertise in biopsy-driven translational studies. Mathilde obtained her PhD in Pharmacy from Rennes I University (France) and worked as a pharmacist before moving to Canada in 2005. Mathilde also completed a specialized graduate diploma (DESS) in drug development and Clinical Research at the University of Montreal.